Photo by nampoh from unsplash
Figure 2. Changes in the cardiac parameters during treatment with tyrosine kinase inhibitors; DBP — diastolic blood pressure; HR — heart rate; LVEF — left ventricular ejection fraction; NT-proBNP —… Click to show full abstract
Figure 2. Changes in the cardiac parameters during treatment with tyrosine kinase inhibitors; DBP — diastolic blood pressure; HR — heart rate; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal-pro B-type natriuretic peptide; SBP — systolic blood pressure; UTI — urinary tract infection A Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors
Keywords:
kinase inhibitors;
safety novel;
novel non;
cardiovascular safety;
tyrosine kinase
Journal Title: Kardiologia polska
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Kardiologia polska
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!